Search Results
Your search for ,ITS matches 8694 pages
Showing 5151 - 5200Texas Medical Center Names William F. McKeon President and CEO
The Texas Medical Center (TMC) has announced that its Board of Directors has appointed William F. McKeon as President and Chief Executive Officer (CEO) and member of the Board of Directors. Mr. McKeon previously held the position of Executive Vice President, Chief Strategy and Operating Officer....
Wendy S. Rubinstein, MD, PhD, Joins CancerLinQ LLC as Division Director, Clinical Data Management and Curation
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced that Wendy S. Rubinstein, MD, PhD, FACMG, FACP, will be its first Division Director, Clinical Data Management and Curation. Dr. Rubinstein will oversee the team working to securely process and analyze the CancerLinQ®...
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): 2017 Guidelines In 1996, the National Comprehensive Cancer Network® (NCCN®) published its first set of Clinical Practice Guidelines in Oncology®, covering 8 tumor types. Guidelines are now published for more than 60 tumor types and...
FDA OCE Launches Drug Information Soundcast in Clinical Oncology (DISCO)
The FDA Drug Information Soundcast in Clinical Oncology (DISCO) is a new podcast series from the U.S. Food and Drug Administration’s (FDA) Oncology Center of Excellence (OCE), covering new product approvals, emerging safety information for cancer treatments, and other current topics in cancer ...
Robert Vonderheide, MD, DPhil, Named Director of Abramson Cancer Center
Robert Vonderheide, MD, DPhil, has been named the new Director of the Abramson Cancer Center (ACC) of the University of Pennsylvania. He is the Hanna Wise Professor in Cancer Research at the Perelman School of Medicine and currently serves as the ACC’s Associate Director for Translational Research ...
ASCO CEO Reflects on His First Year in Office and What Is Ahead
June 27, 2017, marks the 1-year anniversary since Clifford A. Hudis, MD, FACP, FASCO, began his tenure as Chief Executive Officer of ASCO. With the launch of the national Cancer Moonshot and the changes in the White House and Congress, it has been a year of tremendous activity drawing on all of...
The Role of Meditation in Cancer Care
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies commonly used by patients with cancer. In this installment, authors Shelly Latte-Naor, MD, and Jyothirmai Gubili, MS, present the case...
Daniel W. Kulp, PhD, Joins The Wistar Institute in the Vaccine Center
The Wistar Institute has announced the appointment of Daniel W. Kulp, PhD, as Associate Professor in the Vaccine Center and the Translational Tumor Immunology Program. Dr. Kulp’s research centers on how best to rationally engineer protective immune responses against emerging and harmful infectious ...
Lung Cancer: Hope From Science
The following essay by Paul A. Bunn, Jr, MD, is adapted from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and thebigcasino.org. I grew up in ...
First Extensive Immune Profiling of Sarcomas Shows Possible Susceptibility to Immunotherapy
Sarcomas come in dozens of subtypes. Clinical trial results have been mixed when treating these diverse tumors with immunotherapy, a targeted therapeutic strategy that has success in other cancers. However, a study published by Pollack et al in the journal Cancer suggests how both existing and ...
Study on Women Living With Metastatic Breast Cancer
A study by Mariotto et al investigating the prevalence of women living with metastatic breast cancer in the United States estimates that there are 154,794 women living with the disease. In addition, the median and 5-year relative survival for women initially diagnosed with metastatic breast...
AUA 2017: Studies Examine Bladder Cancer Risk and Mortality in E-Cigarette and Traditional Smokers
Data presented at the 2017 Annual Scientific Meeting of the American Urological Association (AUA) showed harmful links between the use of e-cigarettes and bladder cancer risk, and associated the smoking of traditional cigarettes to a higher risk of mortality among patients with bladder cancer. Even ...
ASCO 2017: Chance of Colon Cancer Recurrence Nearly Cut in Half in Patients Who Consume Nuts
An observational study of 826 patients with stage III colon cancer showed that those who consumed 2 ounces or more of nuts per week had a 42% lower chance of cancer recurrence and 57% lower chance of death than those who did not eat nuts. A secondary analysis revealed the benefit of nut consumption ...
ASCO 2017: Increase in Early-Stage Cancer Diagnoses After Implementation of the Affordable Care Act
An analysis of nearly 273,000 patients showed that between 2013 and 2014 there was a 1% increase in the percentage of breast, lung, and colorectal cancers diagnosed at the earliest, most treatable stage. Considering the thousands of people diagnosed with these cancers annually, a 1% increase in...
ASCO 2017: Adjuvant Capecitabine May Extend Survival in Biliary Tract Cancer
A phase III randomized clinical trial in 447 patients with biliary tract cancers showed that treating the disease with capecitabine after surgery extends survival by a median of 15 months compared to surgery alone. The finding could provide the basis for a new standard of care in the disease. This ...
First-in-Class T-Cell Stimulator Varlilumab in Advanced Solid Tumors
A phase I study reported by Burris et al in the Journal of Clinical Oncology has shown that the first-in-class agonist anti-CD27 antibody varlilumab is well tolerated and active in patients with advanced solid tumors. CD27 is a co-stimulatory molecule on T cells that induces intracellular signaling ...
ESTRO 2017: HDR Brachytherapy in Prostate Cancer Does Not Cause Higher Toxicity, Results in High Patient Satisfaction
Treating prostate cancer with a single, high dose of radiation delivered precisely to the site of the tumor results in good quality of life and fewer trips to the hospital, with adverse side effects that are no worse than if the radiation treatment had been given in several lower doses. These...
ESTRO 2017: ESTRO Announces GIRO, a Project to Save 1 Million Lives in Under 20 Years
Although radiation therapy is an essential part of modern cancer treatment, and is indicated for about half of all new cancer patients, facilities for its provision are sadly lacking in many countries worldwide. Indeed, 29 out of 52 African nations have no radiotherapy facilities whatsoever. At the ...
ESTRO 2017: Cervical Cancer Survivors Frequently Suffer From Long-Term Fatigue, Insomnia, and Hot Flashes
Around half of women who have been treated for locally advanced cervical cancer suffer from symptoms of insomnia, fatigue, or hot flashes at some point, according to new research presented at the European Society for Radiotherapy & Oncology (ESTRO) 36 Conference (Abstract OC-0051). Cervical...
Ensuring Equitable Cancer Care for All Patients
Cancer is the second-leading cause of death across the globe. Significant efforts, such as the National Cancer Moonshot Initiative and The University of Texas MD Anderson Cancer Center’s Moon Shots Program, will drive advances in cancer prevention, screening, and treatment. However, right now,...
A New Book Deals With an Age-Old Crisis: Cancer Patients and Mortality
The field of psycho-oncology began to take hold in the mid-1970s, when the “C” word was beginning to lose its long-held stigmatization, and patients with cancer could finally begin to openly reveal their diagnosis and express their feelings about their life-threatening disease. Despite that social ...
Ahmad Samer Al-Homsi, MD, MBA, to Lead New Bone Marrow Transplantation Initiative at NYU
Hematologist-oncologist Ahmad Samer Al-Homsi, MD, MBA, will lead a new bone marrow transplantation program at New York University (NYU) Langone’s Perlmutter Cancer Center for treating blood-borne cancers and potentially utilize transplantation as an adjunct to immunotherapy for solid tumors. He...
Avelumab in Merkel Cell Carcinoma
On March 23, 2017, avelumab (Bavencio) was granted accelerated approval for treatment of patients aged ≥ 12 years with metastatic Merkel cell carcinoma. Avelumab is the first U.S. Food and Drug Administration–approved product to treat this disease.1,2 Supporting Efficacy Data Approval was based on ...
Expanding Role Seen for Minimal Residual Disease in Managing Multiple Myeloma
Minimal residual disease is a promising biomarker for guiding the management of multiple myeloma that is becoming increasingly important with the advent of more efficacious therapies, according to emerging data and expert opinion. “The story of minimal residual disease in multiple myeloma is like...
Immune System Is Shaping the Future of Multiple Myeloma Treatment
From immunomodulatory agents and proteasome inhibitors to steroids, alkylators, and antibodies, recent years have witnessed an explosion of drug approvals for multiple myeloma. The challenge now, said Amrita Krishnan, MD, FACP, is figuring out how to incorporate them all, particularly in the...
ASCO Selects 2017–2018 Health Policy Fellows
ASCO has announced that Alexander Chin, MD, MBA, and Joanna C. Yang, MD, have been selected for the 2017–2018 ASCO Health Policy Fellowship program, now entering its 2nd year. The fellowship provides early-career oncologists the skills they need to monitor and shape the regulatory and legislative ...
Social Media: A Knowledge-Sharing Tool in Oncology
Social media is a uniquely positioned platform that can spread specific knowledge to a larger audience. Unlike traditional media, it allows anyone to join the conversation, and according to the Pew Research Center, it is here to stay, with 79% of online American adults using Facebook and 24% using...
QOPI® Certification Program Certifies First Practice in Brazil
On April 5, ASCO announced that Instituto de Oncologia do Vale (IOV) was the first practice in Brazil to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). IOV is the second international practice to achieve this milestone in...
ELCC 2017: Development and Validation of Lung Toxicity Prediction Models Aids Effective Use of Radiotherapy in NSCLC
Validation using patient data of an outcome prediction model for the development of dyspnea subsequent to radiotherapy revealed that the prognostic factors in the model did not adequately predict for delta toxicity endpoints, according to results reported by Defraene et al at the 2017 European Lung ...
Donor Spotlight: Conquering Cancer With Kelly Cares Foundation
Kelly Cares Foundation recently became one of the newest supporters of the Conquer Cancer Foundation of ASCO Young Investigator Awards, the flagship program begun in 1984 to support early-career cancer researchers. The mission of Kelly Cares Foundation is to inspire hope by investing resources to...
Cancer Research UK Awards Six U.S. Scientists $87 Million as Part of ‘Grand Challenge’
Cancer Research UK has announced that six leading American scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research. The initial $87 million “Grand Challenge” fund will be distributed across 4 international teams of academics from 6...
Neoadjuvant Immunotherapy in High-Risk Melanoma: A New Approach
Melanoma is an immunogenic tumor, as it expresses various melanoma-specific antigens. However, it is both biologically and clinically heterogeneous. Biologically, it expresses different melanoma antigens and has diverse genetic profiles among different patients. Clinically, it varies in the amount ...
Neo-Bioscore Improves Staging of Breast Cancer Treated With Neoadjuvant Chemotherapy
A new score that incorporates tumor biology and response outperforms conventional histopathologic criteria for the staging of breast cancer treated with neoadjuvant chemotherapy, finds a retrospective validation cohort study.1 Investigators led by John R. Bergquist, MD, MS, MA, a general surgery...
On the Variance of Cancer Outcomes by Time and Geography
A recent study by Mokdad and colleagues, reviewed in this issue of The ASCO Post, looks at cancer demographic data for 28 cancers and compares mortality rates in 1980 to results in 2014.1 Publishing mortality rates by geographic area and the observation of significant differences is not new. The...
ELCC 2017: Study Shows White Blood Cell–Boosting Drugs Safe During Small Cell Lung Cancer Chemoradiotherapy
A late-breaking subanalysis of the phase III CONVERT trial presented by Gomes et al at the 2017 European Lung Cancer Conference (ELCC) shows that white blood cell–boosting drugs are safe during concurrent chemoradiotherapy of small cell lung cancer (SCLC, Abstract LBA2_PR). “The...
WHO to Begin Pilot Prequalification of Biosimilars for Cancer Treatment
This year, the World Health Organization (WHO) will launch a pilot project for prequalifying biosimilar medicines, a step toward making some of the most expensive treatments for cancer more widely available in low- and middle-income countries. The decision comes after a 2-day meeting in Geneva...
‘Out-of-the-Box’ Approach Plus Temozolomide Extends Survival in Glioblastoma
Using a novel approach called tumor-treating fields—which involves the delivery of low-intensity electric fields to the brain by a patient-operated device—along with standard-of-care temozolomide therapy improved overall survival and progression-free survival vs temozolomide alone in patients with...
CDK4/6 Inhibitors: Where They Are Now and Where They Are Headed in the Future
Geoffrey I. Shapiro, MD, PhD, Director of the Early Drug Development Center at the Dana-Farber Cancer Institute, Boston, explained the current research initiatives involving cyclin D–dependent kinase (CDK) 4/6 inhibitors. Mechanism of Action How do CDK4/6 inhibitors work at the cellular level in...
CDK4/6 Inhibitors: Their Role in Breast Cancer
The robust progression-free survival benefits achieved with the use of the CDK4/6 inhibitors palbociclib or ribociclib in the metastatic setting provided the impetus to study these agents in early-stage breast cancer. Adjuvant studies are underway, but they take time to mature. For evaluating...
Continuing Education Information
This CE/CME/CEU-accredited supplement is jointly provided by To earn credit/contact hours, you must read all the articles in this supplement and then go to: https://education.annenberg.net/cdk46inhibition Release date: May 10, 2017 Expiration date: May 10, 2018Annenberg Center for Health...
Children Conceived After Fertility Treatments May Be at Increased Risk for Pediatric Cancers
Researchers at Ben-Gurion University of the Negev have found that babies born to mothers who underwent fertility treatments may be at increased risk of developing types of pediatric malignancies and neoplasms. The study, published by Wainstock et al in the American Journal of Obstetrics &...
ASCO Applauds Congress for Providing Additional $2 Billion in NIH Funding
On May 1, Congress announced a bipartisan 2017 budget deal that contains a $2 billion increase in medical research funding for the National Institutes of Health (NIH), including $475 million more for the National Cancer Institute. The budget also maintains funding for cancer control programs at the ...
Joint Position Statement on Management of Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women With Hormone-Sensitive Breast Cancer
A new position statement, jointly published by seven international and European organizations, identifies fracture-related risk factors in patients treated with aromatase inhibitors and outlines key management strategies to help prevent bone loss and related fractures. It was published by Hadji et...
Clinical Practice Guidelines on the Evidence-Based Use of Integrative Therapies During and After Breast Cancer Treatment
In newly updated clinical guidelines from the Society for Integrative Oncology (SIO), researchers at Columbia University's Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center, along with an interdisciplinary team of colleagues at The University of Texas MD Anderson...
Noninvasive Imaging Test May Accurately Rule Out Kidney Cancers
The latest in a series of studies led by researchers at Johns Hopkins Medicine shows that addition of a widely available, noninvasive imaging test called 99mTc-sestamibi SPECT/CT (single-photon emission computed tomography plus computed tomography) to conventional CT or magnetic resonance imaging...
Pigmented Vascular Tumor
Nevus Vasculaire Albumen Print, Paris, 1869 Published in 1869, Revue Photographique des Hôpitaux de Paris was the world’s first medical journal to contain real photographs. In the seven issues produced between 1869 and 1875, 245 images were used. Dr. A. de Montméja, a Parisian ophthalmologist and...
Study Associates Comorbidities With Survival Outcomes in Women With Ovarian Cancer
Research from epidemiologists at Roswell Park Cancer Institute, published by Minlikeeva et al in Cancer Causes & Control, suggests that hypertension and diabetes and the use of medications to treat these comorbidities may have an effect on survival outcomes in women with ovarian cancer. Study...
Keith T. Flaherty, MD, Named New Editor-in-Chief of Clinical Cancer Research
The American Association for Cancer Research (AACR) recently announced the appointment of Keith T. Flaherty, MD, as Editor-in-Chief of Clinical Cancer Research. Dr. Flaherty is Director of the Termeer Center for Targeted Therapies and Director of Clinical Research at the Massachusetts General...
Utilizing Physiatrists to Evaluate and Manage Cancer-Related Cognitive Impairment
Chemotherapy-associated cognitive dysfunction, often referred to as “chemobrain” or “chemofog,” is a common occurrence during active cancer treatment and may continue after treatment is completed. However, since treatment other than chemotherapy, including radiation therapy, surgery, and hormonal...
Olaparib Maintenance in Ovarian Cancer: Outcomes Reconsidered
An article that appeared in the April 10 issue of The ASCO Post (“Olaparib Maintenance Prolongs Progression-Free Survival in Ovarian Cancer”) suggests unwarranted conclusions from the phase III SOLO2 trial of olaparib (Lynparza) in patients with platinum-sensitive relapsed ovarian cancer and...
